BBlogFlow

Overcoming the Wall: How Far Has BBB-Crossing Antibody Technology Truly Advanced? - Commentary by Unexakorea - BioSpace

·Jan 26, 2026

This story deserves to be shared

Send it to someone who'd care, or post it on your networks.

Facebook Twitter Email

This article is an excerpt. To read the full content, visit the original source. BioSpace

Reactions

0 comments

No comments yet. Be the first to share your thoughts!

Facebook Twitter

Related articles

Walid Kamoun Highlights Next-Generation In Vivo Antibody–ADC Click Technology - Oncodaily

“In all the innovative ADC approaches, this paper might reflect a next-next generation approach. Simó et al., in Nature, presents an In Vivo antibody ADC click technology. The design is bioorthogonal chemistry. A therapeutic antibody is conjugated with trans-cyclooctene, an ADC with tetrazine. The two are given sequentially and ligate in vivo after systemic delivery, forming a functional antibody-ADC click construct at the tumour.

Oncodaily·